Difference between TC and AC chemotherapy

TC regimen

is composed of paclitaxel and carboplatin. Paclitaxel inhibits mitosis of tumor cells by promoting tubulin polymerization and inhibiting depolymerization. Carboplatin plays an anti-tumor role by forming cross-links with DNA and destroying DNA functions. TC regimen is commonly used in the treatment of breast cancer, ovarian cancer, etc. AC

regimen is composed of doxorubicin (doxorubicin) and cyclophosphamide. doxorubicin can insert between DNA base pairs, interfere with transcription process, prevent mRNA formation, thereby inhibiting tumor cell growth and reproduction. Cyclophosphamide can interfere with DNA and RNA function, and has significant effects on proliferating cells. AC regimen is often used in the treatment of malignant tumors such as breast cancer.

In the specific application, doctors will comprehensively consider the appropriate regimen according to the patient's condition, physical condition, tumor characteristics and other factors. TC regimen has relatively mild bone marrow suppression, but there may be adverse reactions such as allergic reactions. AC regimen has relatively high cardiotoxicity, requiring close monitoring of cardiac function. At the same time, there may be differences between the two regimens in terms of efficacy, time and extent of adverse reactions. In the course of chemotherapy, we should pay close attention to the adverse reactions of patients, and timely handle and adjust them to ensure the safety and effectiveness of treatment.